Residual Disease and Immune Infiltration as a New Surrogate Endpoint for TNBC Post Neoadjuvant Chemotherapy
Oncotarget - United States
doi 10.18632/oncotarget.27081
Full Text
Open PDFAbstract
Available in full text
Categories
Date
July 4, 2019
Authors
Publisher
Impact Journals, LLC